Monday, March 11, 2019

Biotech Stocks In Focus: ALDX, AXSM, DERM...

The clinical trial results of a drug company can impact its stock price depending upon the outcome - and more so if it is a small-/mid-cap biopharma stock. A keen understanding of the target timeline of the clinical trials will help trade biotech stocks with some margin of safety around the catalyst events.

from RTT - Biotech https://ift.tt/2TKUncM
via IFTTT

No comments:

Post a Comment